Minocycline selectively inhibits M1 polarization of microglia

Cell Death and Disease

Volumn 4, Issue 3, 2013, Pages

  Kobayashi, K ^a   Imagama, S ^a   Ohgomori, T ^a   Hirano, K ^a   Uchimura, K ^a   Sakamoto, K ^a   Hirakawa, A ^a   Takeuchi, H ^b   Suzumura, A ^b   Ishiguro, N ^a   Kadomatsu, K ^a  

^a NAGOYA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b NAGOYA UNIVERSITY   (Japan)

Author keywords

Amyotrophic lateral sclerosis; Microglia; Minocycline; Polarization

Indexed keywords

CD68 ANTIGEN; CD86 ANTIGEN; COPPER ZINC SUPEROXIDE DISMUTASE; GAMMA INTERFERON; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 1BETA; INTERLEUKIN 4; LIPOPOLYSACCHARIDE; MINOCYCLINE; TUMOR NECROSIS FACTOR ALPHA; ACTIN BINDING PROTEIN; AIF1 PROTEIN, MOUSE; ANTIINFECTIVE AGENT; CALCIUM BINDING PROTEIN; SUPEROXIDE DISMUTASE;

AMYOTROPHIC LATERAL SCLEROSIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIGEN EXPRESSION; ARTICLE; CELL ACTIVATION; CELL STIMULATION; CONTROLLED STUDY; DISEASE COURSE; IN VITRO STUDY; MICROGLIA; MOUSE; NERVE CELL CULTURE; NONHUMAN; POLARIZATION; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN SYNTHESIS INHIBITION; SPINAL CORD NERVE CELL; TRANSCRIPTION REGULATION; UPREGULATION; ANIMAL; CELL CULTURE; CYTOLOGY; DISEASE MODEL; DRUG EFFECT; GENETICS; HUMAN; INFLAMMATION; METABOLISM; MORTALITY; PATHOLOGY; SPINAL CORD; SURVIVAL RATE; TRANSGENIC MOUSE;

MUS;

AMYOTROPHIC LATERAL SCLEROSIS; ANIMALS; ANTI-BACTERIAL AGENTS; ANTIGENS, CD86; CALCIUM-BINDING PROTEINS; CELLS, CULTURED; DISEASE MODELS, ANIMAL; HUMANS; INFLAMMATION; INTERLEUKIN-4; LIPOPOLYSACCHARIDES; MICE; MICE, TRANSGENIC; MICROFILAMENT PROTEINS; MICROGLIA; MINOCYCLINE; NF-KAPPA B; SPINAL CORD; SUPEROXIDE DISMUTASE; SURVIVAL RATE; UP-REGULATION;

MLCS; MLOWN;

EID: 84875880772     PISSN: None     EISSN: 20414889     Source Type: Journal    
DOI: 10.1038/cddis.2013.54     Document Type: Article

References (29)

1. Ince PG, Highley JR, Kirby J, Wharton SB, Takahashi H, Strong MJ et al. Molecular pathology and genetic advances in amyotrophic lateral sclerosis: An emerging molecular pathway and the significance of glial pathology. Acta Neuropathol 2011; 122: 657-671.
2. Clement AM, Nguyen MD, Roberts EA, Garcia ML, Boillée S, Rule M et al. Wild-type nonneuronal cells extend survival of SOD1 mutant motor neurons in ALS mice. Science 2003; 302: 113-117.
3. Di Giorgio FP, Carrasco MA, Siao MC, Maniatis T, Eggan K. Non-cell autonomous effect of glia on motor neurons in an embryonic stem cell-based ALS model. Nat Neurosci 2007; 10: 608-614.
4. Nagai M, Re DB, Nagata T, Chalazonitis A, Jessell TM, Wichterle H et al. Astrocytes expressing ALS-linked mutated SOD1 release factors selectively toxic to motor neurons. Nat Neurosci 2007; 10: 615-622.
5. Vargas MR, Pehar M, Cassina P, Martínez-Palma L, Thompson JA, Beckman JS et al. Fibroblast growth factor-1 induces heme oxygenase-1 via nuclear factor erythroid 2-related factor 2 (Nrf2) in spinal cord astrocytes: Consequences for motor neuron survival. J Biol Chem 2005; 280: 25571-25579.
6. Boillée S, Vande Velde C, Cleveland DW. ALS: A disease of motor neurons and their nonneuronal neighbors. Neuron 2006; 52: 39-59.
7. McGeer EG, McGeer PL. Pharmacologic approaches to the treatment of amyotrophic lateral sclerosis. BioDrugs 2005; 19: 31-37.
8. Liao B, ZhaoW, Beers DR, Henkel JS, Appel SH. Transformation from a neuroprotective to a neurotoxic microglial phenotype in a mouse model of ALS. Exp Neurol 2012; 237: 147-152.
9. Kigerl KA, Gensel JC, Ankeny DP, Alexander JK, Donnelly DJ, Popovich PG et al. Identification of two distinct macrophage subsets with divergent effects causing either neurotoxicity or regeneration in the injured mouse spinal cord. J Neurosci 2009; 29: 13435-13444.
10. Meissner F, Molawi K, Zychlinsky A. Mutant superoxide dismutase 1-induced IL-1beta accelerates ALS pathogenesis. Proc Natl Acad Sci USA 2010; 107: 13046-13050.
11. David S, Kroner A. Repertoire of microglial and macrophage responses after spinal cord injury. Nat Rev Neurosci 2011; 12: 388-399.
12. Ponomarev ED, Maresz K, Tan Y, Dittel BN. CNS-derived interleukin-4 is essential for the regulation of autoimmune inflammation and induces a state of alternative activation in microglial cells. J Neurosci 2007; 27: 10714-10721.
13. Beers DR, Henkel JS, Zhao W, Wang J, Huang A, Wen S et al. Endogenous regulatory T lymphocytes ameliorate amyotrophic lateral sclerosis in mice and correlate with disease progression in patients with amyotrophic lateral sclerosis. Brain 2011; 134: 1293-1314.
14. Kriz J, Nguyen MD, Julien JP. Minocycline slows disease progression in a mouse model of amyotrophic lateral sclerosis. Neurobiol Dis 2002; 10: 268-378.
15. Van Den Bosch L, Tilkin P, Lemmens G, Robberecht W. Minocycline delays disease onset and mortality in a transgenic model of ALS. Neuroreport 2002; 13: 1067-1070.
16. Zhu S, Stavrovskaya IG, Drozda M, Kim BY, Ona V, Li M et al. Minocycline inhibits cytochrome c release and delays progression of amyotrophic lateral sclerosis in mice. Nature 2002; 417: 74-78.
17. Kriz J, Gowing G, Julien JP. Efficient three-drug cocktail for disease induced by mutant superoxide dismutase. Ann Neurol 2003; 53: 429-436.
18. Zhang W, Narayanan M, Friedlander RM. Additive neuroprotective effects of minocycline with creatine in a mouse model of ALS. Ann Neurol 2003; 53: 267-270.
19. Keller AF, Gravel M, Kriz J. Treatment with minocycline after disease onset alters astrocyte reactivity and increases microgliosis in SOD1 mutant mice. Exp Neurol 2011; 228: 69-79.
20. Gordon PH, Moore DH, Miller RG, Florence JM, Verheijde JL, Doorish C et al. Efficacy of minocycline in patients with amyotrophic lateral sclerosis: A phase III randomised trial. Lancet Neurol 2007; 6: 1045-1053.
21. Li Q, Verma IM. NF-kappa B regulation in the immune system. Nat Rev Immunol 2002; 2: 725-734.
22. Kennedy MN, Mullen GE, Leifer CA, Lee C, Mazzoni A, Dileepan KN et al. A complex of soluble MD-2 and lipopolysaccharide serves as an activating ligand for Toll-like receptor 4. J Biol Chem 2004; 279: 34698-34704.
23. Akira S, Takeda K. Toll-like receptor signalling. Nat Rev Immunol 2004; 4: 499-511.
24. Pang T, Wang J, Benicky J, Saavedra JM. Minocycline ameliorates LPS-induced inflammation in human monocytes by novel mechanisms including LOX-1, Nur77 and LITAF inhibition. Biochim Biophys Acta 2012; 1820: 503-510.
25. Liu Y, HaoW, Dawson A, Liu S, Fassbender K. Expression of amyotrophic lateral sclerosislinked SOD1 mutant increases the neurotoxic potential of microglia via TLR2. J Biol Chem 2009; 284: 3691-3699.
26. Zhao W, Beers DR, Henkel JS, Zhang W, Urushitani M, Julien JP et al. Extracellular mutant SOD1 induces microglial-mediated motoneuron injury. Glia 2010; 58: 231-243.
27. Swarup V, Phaneuf D, Dupré N, Petri S, Strong M, Kriz J et al. Deregulation of TDP-43 in amyotrophic lateral sclerosis triggers nuclear factor kB-mediated pathogenic pathways. J Exp Med 2011; 208: 2429-2447.
28. Butovsky O, Siddiqui S, Gabriely G, Lanser AJ, Dake B, Murugaiyan G et al. Modulating inflammatory monocytes with a unique microRNA gene signature ameliorates murine ALS. J Clin Invest 2012; 122: 3063-3087.
29. Takeuchi H, Mizoguchi H, Doi Y, Jin S, Noda M, Liang J et al. Blockade of gap junction hemichannel suppresses disease progression in mouse models of amyotrophic lateral sclerosis and Alzheimer's disease. PLoS ONE 2011; 6: E21108.